Article Sidebar

PDF
Date Published: 06/11/2023
Online Published: 06/11/2023
Abstract Views: 485
Views PDF: 320
DOI: https://doi.org/10.58490/ctump.2023i67.2195
Issue
No. 67 (2023)
Section
Article
How to Cite
Vo, T. C., Nguyen, T. V., Vo, P. M. T., & Ngo, T. Y. N. (2023). UPDATE ON ANTIBIOTICS USE IN MULTI-RESISTANT GRAM- NEGATIVE INFECTION ACCORDING TO GUIDELINE IDSA 2023. Cantho Journal of Medicine and Pharmacy, 67, 158-168. https://doi.org/10.58490/ctump.2023i67.2195

UPDATE ON ANTIBIOTICS USE IN MULTI-RESISTANT GRAM- NEGATIVE INFECTION ACCORDING TO GUIDELINE IDSA 2023

Tan Cuong Vo1,, Thien Vu Nguyen1, Pham Minh Thu Vo2, Thi Yen Nhi Ngo1
1 Can Tho University of Medicine and Pharmacy Hospital
2 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

According to the World Health Organization (WHO), antibiotic resistance (AMR) is one of the 10 global public health threats facing humanity. In Vietnam, most medical and treatment facilities are facing the rapid spread of antibiotic-resistant bacteria with many types of antibiotics and the emergence of bacteria resistant to most antibiotics, also known as super-reflective drug bacteria. On June 7, 2023, the Infectious Diseases Society of America (IDSA) continued to update promotional programs on the treatment of infections caused by multidrug-resistant Gram-negative strains. The guideline focuses on solutions for selecting priority and alternative antibiotics in the treatment of Enterobacterales strains commonly producing β-lactamase (ESBL-E), Enterobacterales producing AmpC β-lactamase (AmpC-E), Carbapenem-resistant Enterobacterales (CRE), Treatment-resistant Pseudomonas aeruginosa (DTR-P. aeruginosa), Carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia. Instructions apply to both adults and children.

Article Details

Keywords

Antimicrobial resistance, Multidrug-resistant Gram-negative, IDSA

References

1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022. 399(10325), 629-55, https://doi.org/10.1016/S01406736(21)02724-0
2. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States 2019. Centers for Disease Control and Prevention. 2019. http://dx.doi.org/10.15620/cdc:82532.
3. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections. Infectious Diseases Society of America. 2023. DOI: 10.1093/cid/ciad428
4. Tamma PD, Smith TT, Adebayo A, et al. Prevalence of blaCTX-M Genes in Gram-Negative Bloodstream Isolates across 66 Hospitals in the United States. J Clin Microbiol. 2021. 59(6). DOI: 10.1128/JCM.00127-21
5. Castanheira M, Kimbrough JH, DeVries S, Mendes RE, Sader HS. Trends of beta-Lactamase Occurrence Among Escherichia coli and Klebsiella pneumoniae in United States Hospitals
During a 5-Year Period and Activity of Antimicrobial Agents Against Isolates Stratified by beta-
Lactamase Type. Open Forum Infect Dis. 2023. 10(2). DOI: 10.1093/ofid/ofad038
6. Bush K, Bradford PA. Epidemiology of beta-Lactamase-Producing Pathogens. Clin Microbiol Rev. 2020. 33(2). DOI: 10.1128/CMR.00047-19
7. Chou A, Welch E, Hunter A, Trautner BW. Antimicrobial Treatment Options for Difficult-toTreat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review. Drugs. 2022. 82(4), 407-438. DOI: 10.1007/s40265-022-01676-5
8. Tamma PD, Rodríguez-Baño J. The Use of Noncarbapenem beta-Lactams for the Treatment of Extended-Spectrum beta-Lactamase Infections. Clin Infect Dis. 2017. 64(7), 972-980. DOI: 10.1093/cid/cix034
9. Tamma PD, Doi Y, Bonomo RA, Johnson JK, Simner PJ, Antibacterial Resistance Leadership G. A Primer on AmpC beta-Lactamases: Necessary Knowledge for an Increasingly Multidrugresistant World. Clin Infect Dis. 2019. 69(8), 1446-1455. DOI: 10.1093/cid/ciz173
10. Tan SH, Ng TM, Chew KL, et al. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems. Int J Antimicrob Agents. 2020. 55(2). DOI: 10.1016/j.ijantimicag.2019.105860
11. Sabour S, Huang Y, Bhatnagar A, et al. Detection and Characterization of Targeted
Carbapenem-Resistant Healthcare-Associated Threats: Findings from The Antibiotic Resistance Laboratory Network, 2017 to 2019. Antimicrob Agents Chemother. 2021. 65. DOI: 10.1128/AAC.01105-21
12. Horwich-Scholefield S, Lloyd T, Varghese V, Yette E, Huang S, Pandori M. ImipenemRelebactam Susceptibility and Genotypic Characteristics of Carbapenem-Resistant Enterobacterales (CRE) Identified during Population-Based Surveillance. Antimicrob Agents Chemother. 2021. DOI: 10.1128/AAC.02288-20
13. Shields RK, Stellfox ME, Kline EG, Samanta P, Van Tyne D. Evolution of ImipenemRelebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia. Clin Infect Dis. 2022. 75(4), 710-714. DOI: 10.1093/cid/ciac097
14. O'Donnell JN, Putra V, Lodise TP. Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options? Pharmacotherapy. 2021. 41, 762-780. DOI: 10.1002/phar.2607
15. Karaba SM, Goodman KE, Amoah J, Cosgrove SE, Tamma PD. StenoSCORE: Predicting Stenotrophomonas maltophilia Bloodstream Infections in the Hematologic Malignancy Population. Antimicrob Agents Chemother. 2021. 65(8). doi: 10.1128/AAC.00793-21